Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
She joins Enveda from Gilead Sciences
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Post this currently only Risperidone orally disintegrating tablets are allowed for import into the US from the Roorkee facility.
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
MedTel aims to raise series A for rapid business expansion, product improvement & conducting relevant clinical validation studies.
Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Subscribe To Our Newsletter & Stay Updated